AQR Capital Management
BDTX icon

AQR Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

AQR Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,026
Closed -$68.3K – 3574
2025
Q3 		$68.3K Sell
18,026
-195,211
-92% -$571K ﹤0.01% 3401
2025
Q2 		$529K Buy
213,237
+159,115
+294% +$307K ﹤0.01% 2592
2025
Q1 		$83.9K Buy
+54,122
New +$113K ﹤0.01% 3040
2024
Q4 		– Sell
-15,692
Closed -$68.3K – 2875
2024
Q3 		$68.3K Buy
+15,692
New +$85.4K ﹤0.01% 2688
2022
Q3 		– Sell
-18,663
Closed -$46K – 2200
2022
Q2 		$46K Buy
18,663
+4,773
+34% +$11.1K ﹤0.01% 2138
2022
Q1 		$38K Buy
+13,890
New +$50.7K ﹤0.01% 2190

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management's BDTX Position: Q4 2025 in Review

AQR Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q4 2025, closing a stake of 18,026 shares — an estimated $68.3K sold.

AQR Capital Management first reported a position in BDTX in Q1 2022 and held it in 6 quarters. The position peaked at $529K in Q2 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q4 2025.

  • AQR Capital Management reported no remaining Black Diamond Therapeutics position as of Q4 2025 after selling out during the quarter.
  • AQR Capital Management sold 18,026 Black Diamond Therapeutics shares in Q4 2025, an estimated $68.3K.
  • AQR Capital Management first reported a position in Black Diamond Therapeutics in Q1 2022 and held it in 6 quarters.
  • AQR Capital Management's Black Diamond Therapeutics position peaked at $529K in Q2 2025.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2025.

Based on AQR Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.